HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Open accessAbstract
Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The response of HER2 mutant cancers to HER2 inhibition varies depending on the tissue-of-origin of the cancer.
“the response of HER2 mutant cancers to HER2 inhibition varies depending on the tissue-of-origin of the cancer84”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [84]
Clinical testing of afatinib, neratinib, and dacomitinib achieved overall response rates of 8.7%, 9.5%, and 12%, respectively, for patients harboring EGFR or HER2 exon 20 mutations.
“In concordance with this, clinical testing of afatinib, neratinib, and dacomitinib achieved overall response rates of 8.7%, 9.5%, and 12%, respectively, for patients harboring EGFR or HER2 exon 20 mutations25,42,46,47.”
From Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077 · see citing works
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works
Self-citationSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302 · see citing works
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,029 · see citing works
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777 · see citing works
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works
Self-citationVogel, C. L., Cobleigh, M., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.719 · Cited by 3,240 · see citing works
OncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R. D., Soumerai, T. E., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,732 · see citing works
Self-citationPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164 · see citing works
Self-citationMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119 · see citing works
Self-citationAbsolute quantification of somatic DNA alterations in human cancer
Carter, S., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P., Onofrio, R., Winckler, W., Weir, B., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 1,975 · see citing works
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860 · see citing works
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · see citing works
Self-citationOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,707 · see citing works
Baselga, J. M., Tripathy, D., Mendelsohn, J. M., Baughman, S. A., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J. L., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,382 · see citing works
Self-citationBaselga, J. M., Bradbury, I., Eidtmann, H., Cosimo, S. D., de Azambuja, E., Aura, C. M., Gómez, H., Dinh, P., Fauria, K., Dooren, V. V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317 · see citing works
Self-citationShen, R., & Seshan, V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw520 · Cited by 1,263 · see citing works
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016 · see citing works
Blackwell, K., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G. W., Koehler, M. T., Ellis, C. E., Casey, M., Vukelja, S. J., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 940 · see citing works
Self-citationBertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · see citing works
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J. D., Goel, N. J., Aronson, A. B., Li, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 869 · see citing works
MSIsensor: microsatellite instability detection using paired tumor-normal sequence data
Niu, B., Ye, K., Zhang, Q., Lu, C., Xie, M., McLellan, M. D., Wendl, M. C., & Ding, L. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt755 · Cited by 821 · see citing works
Chang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C., Gao, J., Socci, N. D., Solit, D. B., Olshen, A. B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3391 · Cited by 808 · see citing works
Self-citationClonal status of actionable driver events and the timing of mutational processes in cancer evolution
McGranahan, N., Favero, F., de Bruin, E. C., Birkbak, N. J., Szallasi, Z., & Swanton, C. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1408 · Cited by 685 · see citing works
Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1337 · Cited by 643 · see citing works
Self-citationYasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571 · see citing works
Implementing Genome-Driven Oncology
Hyman, D. M., Taylor, B. S., & Baselga, J. M. (2017) · Cell · doi:10.1016/j.cell.2016.12.015 · Cited by 505 · see citing works
Self-citationAccelerating Discovery of Functional Mutant Alleles in Cancer
Chang, M. T., Shrestha-Bhattarai, T., Schram, A. M., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., Chakravarty, D., Phillips, S. M., Kandoth, C., Penson, A. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0321 · Cited by 402 · see citing works
Self-citationExploring genomic alteration in pediatric cancer using ProteinPaint
Zhou, X., Edmonson, M. N., Wilkinson, M. R., Patel, A., Wu, G., Liu, Y., Li, Y., Zhang, Z., Rusch, M., Parker, M. D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3466 · Cited by 395 · see citing works
Middha, S., Zhang, L., Nafa, K., Jayakumaran, G., Wong, D., Kim, H. R., Sadowska, J., Berger, M. F., DeLair, D. F., Shia, J., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00084 · Cited by 379 · see citing works
Self-citationBaselga, J. M., Cortés, J., Im, S., Clark, E., Ross, G. A., Kiermaier, A. C., & Swain, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5384 · Cited by 364 · see citing works
Self-citationOncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350 · see citing works
AKT Inhibition in Solid Tumors With AKT1 Mutations
Hyman, D. M., Smyth, L. M., Donoghue, M. T. A., Westin, S. N., Bedard, P. L., Dean, E. J., Bando, H., El-Khoueiry, A. B., Fidalgo, J. A. P., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0143 · Cited by 309 · see citing works
Self-citationHER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1211 · Cited by 302 · see citing works
Loibl, S., Majewski, I. J., Guarneri, V., Nekljudova, V., Holmes, E. M., Bria, E., Denkert, C., Schem, C., Sotiriou, C. P., Loi, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw197 · Cited by 230 · see citing works
Self-citationMa, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E., Naughton, M., Goetz, M. P., Russell, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0900 · Cited by 193 · see citing works
Self-citationFreedman, R. A., Gelman, R. S., Wefel, J. S., Melisko, M., Hess, K. R., Connolly, R. M., Poznak, C. H. V., Niravath, P. A., Puhalla, S. L., Ibrahim, N. K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0343 · Cited by 172 · see citing works
Ross, J. S., Wang, K., Gay, L. M., Al-Rohil, R. N., Nazeer, T., Sheehan, C. E., Jennings, T. A., Otto, G. A., Donahue, A. L., He, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1992 · Cited by 145 · see citing works
Ross, J. S., Wang, K., Sheehan, C. E., Boguniewicz, A. B., Otto, G., Downing, S. R., Sun, J., He, J., Curran, J. A., Ali, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0295 · Cited by 135 · see citing works
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3404 · Cited by 131 · see citing works
Chmielecki, J., Ross, J. S., Wang, K., Frampton, G. M., Palmer, G. A., Ali, S. M., Palma, N. A., Morosini, D., Miller, V. A., Yelensky, R., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0234 · Cited by 101 · see citing works
HER2 missense mutations have distinct effects on oncogenic signaling and migration
Zabransky, D. J., Yankaskas, C. L., Cochran, R. L., Wong, H. Y., Croessmann, S., Chu, D. T. W., Kavuri, S. M., Brewer, M. R., Rosen, D. M., Dalton, W. B., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516853112 · Cited by 83 · see citing works
Self-citationHyman, D. M., Laetsch, T. W., Kummar, S., DuBois, S. G., Farago, A. F., Pappo, A. S., Demetri, G. D., El‐Deiry, W. S., Lassen, U., Dowlati, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.18_suppl.lba2501 · Cited by 77 · see citing works
Self-citationShi, W., Jiang, T., Nuciforo, P. G., Hatzis, C., Holmes, E. M., Harbeck, N., Sotiriou, C., Peña, L., Loi, S., Rosa, D. D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw434 · Cited by 76 · see citing works
Self-citationGiri, V. N., Obeid, E. I., Gross, L., Bealin, L., Hyatt, C., Hegarty, S., Montgomery, S. V., Forman, A. D., Bingler, R., Kelly, W. K., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00039 · Cited by 68 · see citing works
Chumsri, S., Weidler, J. M., Ali, S. M., Balasubramanian, S., Wallweber, G. J., Eli, L. D., Chenna, A., Huang, W., DeRidder, A. M., Goicocheal, L., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0132 · Cited by 42 · see citing works
Self-citationHyman, D. M., Laetsch, T. W., Kummar, S., DuBois, S. G., Farago, A. F., Pappo, A. S., Demetri, G. D., El‐Deiry, W. S., Lassen, U., Dowlati, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.lba2501 · Cited by 27 · see citing works
Self-citationPrecision oncology: Charting a path forward to broader deployment of genomic profiling
Schram, A. M., Berger, M. F., & Hyman, D. M. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002242 · Cited by 20 · see citing works
Self-citationSchram, A. M., Won, H. H., André, F., Arnedos, M., Meric‐Bernstam, F., Bedard, P. L., Shaw, K. R. M., Horlings, H. M., Micheel, C., Park, B. H., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-lb-103 · Cited by 8 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- [39]Zehir A Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Nat Med 23 703 713 2017 28481359 PMC5461196
- [41]Chang MT Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity Nat Biotechnol 34 155 63 2016 26619011 PMC4744099
Cited by
Sorted by citations
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024 · see citing works
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274 · see citing works
Network pharmacology: curing causal mechanisms instead of treating symptoms
Nogales, C., Mamdouh, Z. M., List, M., Kiel, C., Casas, A. I., & Schmidt, H. H. H. W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.004 · Cited by 1,232 · see citing works
Mosele, F., Remón, J., Mateo, J., Westphalen, C. B., Barlési, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M. E., Meric‐Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,204 · see citing works
Self-citationTargeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160 · see citing works
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081 · see citing works
Valle, J. W., Kelley, R. K., Nervi, B., Oh, D., & Zhu, A. X. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00153-7 · Cited by 1,068 · see citing works
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L. A., Saltos, A. N., Felip, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,046 · see citing works
Self-citationThe Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.008 · Cited by 993 · see citing works
Self-citationPersonalized medicine: motivation, challenges, and progress
Goetz, L. H., & Schork, N. J. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.006 · Cited by 976 · see citing works
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783 · see citing works
Small molecules, big impact: 20 years of targeted therapy in oncology
Bedard, P. L., Hyman, D. M., Davids, M. S., & Siu, L. L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30164-1 · Cited by 616 · see citing works
Self-citationLi, B. T., Shen, R., Buonocore, D. J., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M. D., Feldman, D., Hembrough, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9777 · Cited by 557 · see citing works
Self-citationRational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503 · see citing works
Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468 · see citing works
Mosele, M. F., Westphalen, C. B., Stenzinger, A., Barlési, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 443 · see citing works
Self-citationJavle, M. M., Borad, M. J., Azad, N. S., Kurzrock, R., Abou‐Alfa, G. K., George, B., Hainsworth, J. D., Meric‐Bernstam, F., Swanton, C., Sweeney, C. J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00336-3 · Cited by 429 · see citing works
Self-citationEvolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Marchiò, C., Annaratone, L., Marques, A., Casorzo, L., Berrino, E., & Sapino, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.016 · Cited by 387 · see citing works
Turner, N. C., Kingston, B., Kilburn, L., Kernaghan, S., Wardley, A. M., Macpherson, I. R., Baird, R. D., Roylance, R. R., Stephens, P., Oikonomidou, O., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30444-7 · Cited by 376 · see citing works
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Lamarca, Á., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.007 · Cited by 367 · see citing works
Tsurutani, J., Iwata, H., Krop, I. E., Janne, P. A., Doi, T., Takahashi, S., Park, H., Redfern, C. H., Tamura, K., Wise-Draper, T. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1014 · Cited by 356 · see citing works
Self-citationAdvances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Meric‐Bernstam, F., Johnson, A. M., Dumbrava, E. E. I., Raghav, K. P. S., Balaji, K., Bhatt, M., Murthy, R. K., Rodon, J. A., & Piha-Paul, S. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2275 · Cited by 345 · see citing works
Self-citationSignaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 332 · see citing works
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z., Teng, Q., Qin, T. L., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 325 · see citing works
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320 · see citing works
Marra, A., Trapani, D., Viale, G., Criscitiello, C., & Curigliano, G. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00197-2 · Cited by 316 · see citing works
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Montal, R., Sia, D., Montironi, C., Leow, W. Q., Esteban-Fabró, R., Pinyol, R., Torres‐Martín, M., Bassaganyas, L., Moeini, A., Peix, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.008 · Cited by 304 · see citing works
Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0126 · Cited by 290 · see citing works
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Li, B. T., Michelini, F., Misale, S., Cocco, E., Baldino, L., Cai, Y., Shifman, S. G., Tu, H., Myers, M. L., Xu, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0215 · Cited by 288 · see citing works
Self-citationPersonalized Medicine: Recent Progress in Cancer Therapy
Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., Fleitas, T., Roda, D., & Cervantes, A. M. R. (2020) · Cancers · doi:10.3390/cancers12041009 · Cited by 288 · see citing works
Towards personalized treatment for early stage HER2-positive breast cancer
Goutsouliak, K., Veeraraghavan, J., Sethunath, V., Angelis, C. D., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0299-9 · Cited by 285 · see citing works
Meric‐Bernstam, F., Bahleda, R., Hierro, C., Sanson, M., Bridgewater, J. A., Arkenau, H., Tran, B., Kelley, R. K., Park, J. O., Javle, M. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0697 · Cited by 262 · see citing works
Self-citationThe Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
Velden, D. L. V. D., Hoes, L. R., van der Wijngaart, H., Henegouwen, J. M. V. B., van Werkhoven, E. D., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., et al. (2019) · Nature · doi:10.1038/s41586-019-1600-x · Cited by 259 · see citing works
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
Siena, S., Bianchi, A. S., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F. M., Srock, S., Bardelli, A., & Trusolino, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy100 · Cited by 249 · see citing works
Triple-negative breast cancer: promising prognostic biomarkers currently in development
Sukumar, J. S., Gast, K. C., Quiroga, D. M., Lustberg, M. B., & Williams, N. O. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1840984 · Cited by 246 · see citing works
Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 245 · see citing works
Robichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.001 · Cited by 242 · see citing works
Self-citationPrecision oncology in metastatic colorectal cancer — from biology to medicine
Nicolantonio, F. D., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J. M., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 238 · see citing works
Peters, S., Stahel, R. A., Bubendorf, L., Bonomi, P., Villegas, A. E., Kowalski, D. M., Baik, C. S., Isla, D., de Castro, J., Garrido, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1590 · Cited by 237 · see citing works
Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S. S., Persky, N. S., Marini, L., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0287-5 · Cited by 228 · see citing works
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 226 · see citing works
Self-citationNCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023
Benson, A. B., D'Angelica, M. I., Abrams, T. A., Abbott, D. E., Ahmed, A., Anaya, D. A., Anders, R. A., Are, C., Bachini, M., Binder, D. C., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0035 · Cited by 220 · see citing works
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 216 · see citing works
Wang, Y., Jiang, T., Qin, Z., Jiang, J., Wang, Q., Yang, S., Rivard, C. J., Gao, G., Ng, T. L., Tu, M. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy542 · Cited by 209 · see citing works
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021) · Nature Communications · doi:10.1038/s41467-021-22125-z · Cited by 208 · see citing works
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Friedlaender, A., Subbiah, V., Russo, A., Banna, G. L., Malapelle, U., Rolfo, C. D., & Addeo, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00558-1 · Cited by 203 · see citing works
HER2-targeted therapies in gastric cancer
Zhu, Y., Zhu, X., Wei, X., Tang, C., & Zhang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188549 · Cited by 202 · see citing works
The NCI-MATCH trial: lessons for precision oncology
O'Dwyer, P. J., Gray, R. J., Flaherty, K. T., Chen, A. P., Li, S., Wang, V., McShane, L. M., Patton, D. R., Tricoli, J. V., Williams, P. M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02379-4 · Cited by 198 · see citing works
Self-citationAccelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197 · see citing works
Riudavets, M., Sullivan, I., Abdayem, P., & Planchard, D. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100260 · Cited by 196 · see citing works
Santoni‐Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 195 · see citing works
Weinberg, B. A., Xiu, J., Lindberg, M. R., Shields, A. F., Hwang, J. J., Poorman, K. A., Salem, M. E., Pishvaian, M. J., Holcombe, R. F., Marshall, J. L., et al. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.08.18 · Cited by 185 · see citing works
Next generation sequencing‐based gene panel tests for the management of solid tumors
Nagahashi, M., Shimada, Y., Ichikawa, H., Kameyama, H., Takabe, K., Okuda, S., & Wakai, T. (2018) · Cancer Science · doi:10.1111/cas.13837 · Cited by 178 · see citing works
Huppert, L. A., Gümüşay, Ö., Idossa, D. W., & Rugo, H. S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 178 · see citing works
HER2-targeted therapies beyond breast cancer — an update
Yoon, J., & Oh, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00924-9 · Cited by 171 · see citing works
Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Elvevi, A., Laffusa, A., Scaravaglio, M., Rossi, R. E., Longarini, R., Stagno, A. M., Cristoferi, L., Ciaccio, A., Cortinovis, D. L., Invernizzi, P., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100737 · Cited by 168 · see citing works
Genomics to select treatment for patients with metastatic breast cancer
André, F., Filleron, T., Kamal, M. T., Mosele, F., Arnedos, M., Dalenc, F., Sablin, M., Campone, M., Bonnefoi, H. R., Lefeuvre‐Plesse, C., et al. (2022) · Nature · doi:10.1038/s41586-022-05068-3 · Cited by 167 · see citing works
Tissue-specificity in cancer: The rule, not the exception
Haigis, K. M., Cichowski, K. M., & Elledge, S. J. (2019) · Science · doi:10.1126/science.aaw3472 · Cited by 167 · see citing works
Le, X., Cornelissen, R., Garassino, M. C., Clarke, J. M., Tchekmedyian, N., Goldman, J. W., Leu, S.-Y., Bhat, G., Lebel, F. M., Heymach, J. V., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01323 · Cited by 165 · see citing works
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
Pahuja, K. B., Nguyen, T. T., Jaiswal, B. S., Prabhash, K., Thaker, T. M., Senger, K., Chaudhuri, S., Kljavin, N. M., Antony, A., Phalke, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.010 · Cited by 161 · see citing works
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 157 · see citing works
Pegram, M. D., Jackisch, C., & Johnston, S. R. D. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00533-2 · Cited by 157 · see citing works
Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151 · see citing works
Self-citationKim, S.-Y., Kim, S.-M., Lim, S., Lee, J. Y., Choi, S.-J., Yang, S.-D., Yun, M. R., Kim, C. G., Gu, S. R., Park, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-5026 · Cited by 151 · see citing works
Condorelli, R., Mosele, F., Verret, B., Bachelot, T., Bedard, P. L., Cortés, J., Hyman, D., Juric, D., Krop, I. E., Bièche, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz036 · Cited by 151 · see citing works
Self-citationOncoTree: A Cancer Classification System for Precision Oncology
Kundra, R., Zhang, H., Sheridan, R., Sirintrapun, S. J., Wang, A., Ochoa, A., Wilson, M., Gross, B. E., Sun, Y., Madupuri, R., et al. (2021) · JCO Clinical Cancer Informatics · doi:10.1200/cci.20.00108 · Cited by 149 · see citing works
Self-citationTowards precision oncology with patient-derived xenografts
Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 149 · see citing works
Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 146 · see citing works
Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine
Rossi, G., & Ignatiadis, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3402 · Cited by 144 · see citing works
Dantoing, E., Piton, N., Salaün, M., Thiberville, L., & Guisier, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126288 · Cited by 142 · see citing works
Zhang, G., Ren, C., Li, C., Wang, Y., Chen, B., Wen, L., Jia, M., Li, K., Mok, H., Cao, L., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02346-9 · Cited by 137 · see citing works
The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review
Meyer, E. L., Mesenbrink, P. G., Dunger‐Baldauf, C., Fülle, H., Glimm, E., Li, Y., Posch, M., & König, F. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.05.010 · Cited by 136 · see citing works
Tsai, R. M., Miller, Z., KOESTLER, M. E., Rojas, J. C., Ljubenkov, P. A., Rosen, H. J., Rabinovici, G. D., Fagan, A. M., Cobigo, Y., Brown, J. A., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3812 · Cited by 134 · see citing works
Kurzrock, R., Bowles, D. W., Kang, H., Meric‐Bernstam, F., Hainsworth, J. D., Spigel, D. R., Bose, R., Burris, H. A., Sweeney, C. J., Beattie, M. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.018 · Cited by 133 · see citing works
Self-citationLi, B. T., Meric‐Bernstam, F., Bardia, A., Naito, Y., Siena, S., Aftimos, P., Anderson, I., Curigliano, G., Miguel, M. J. D., Kalra, M., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00140-2 · Cited by 132 · see citing works
Self-citationDagogo-Jack, I., Martinez, P., Yeap, B. Y., Ambrogio, C., Ferris, L. A., Lydon, C., Nguyen, T., Jessop, N. A., Iafrate, A. J., Johnson, B. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2062 · Cited by 130 · see citing works
Marra, A., Chandarlapaty, S., & Modi, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00849-9 · Cited by 130 · see citing works
Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers
Subbiah, V., Puzanov, I. J., Blay, J., Chau, I., Lockhart, A. C., Raje, N. S., Wolf, J., Baselga, J. M., Meric‐Bernstam, F., Roszik, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1265 · Cited by 127 · see citing works
Self-citationHER2-positive advanced breast cancer treatment in 2020
Cesca, M. G., Vian, L., Cristóvão‐Ferreira, S., Ponde, N. F., & de Azambuja, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102033 · Cited by 127 · see citing works
CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers
Tokheim, C. J., & Karchin, R. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.005 · Cited by 124 · see citing works
Consensus for HER2 alterations testing in non-small-cell lung cancer
Ren, S., Wang, J., Ying, J., Mitsudomi, T., Lee, D., Wang, Z., Chu, Q., Mack, P. C., Cheng, Y., Duan, J., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100395 · Cited by 124 · see citing works
Precision medicine becomes reality—tumor type‐agnostic therapy
Li, Y., & Zhang, W. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0274-3 · Cited by 121 · see citing works
Varešlija, D., Priedigkeit, N., Fagan, A., Purcell, S. P., Cosgrove, N. S., O’Halloran, P. J., Ward, E., Cocchiglia, S., Hartmaier, R. J., Castro, C. A., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy110 · Cited by 121 · see citing works
Jin, J., Wu, X., Yin, J., Li, M., Shen, J., Li, J., Zhao, Y., Zhao, Q., Wu, J., Wen, Q., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00263 · Cited by 121 · see citing works
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 121 · see citing works
Ettrich, T. J., Schwerdel, D., Dolnik, A., Beuter, F., Blätte, T. J., Schmidt, S. A., Stanescu-Siegmund, N., Steinacker, J., Marienfeld, R. B., Kleger, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49860-0 · Cited by 120 · see citing works
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 114 · see citing works
Smyth, L. M., Tamura, K., Oliveira, M., Ciruelos, E., Mayer, I. A., Sablin, M., Biganzoli, L., Ambrose, H. J., Ashton, J., Barnicle, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3953 · Cited by 113 · see citing works
Self-citationOu, D., Sun, D., Lin, X., Liang, Z., Zhong, Y., & Chen, Z. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00472f · Cited by 112 · see citing works
Segers, V. F. M., Dugaucquier, L., Feyen, E., Shakeri, H., & Keulenaer, G. W. D. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00499-4 · Cited by 112 · see citing works
Clinicopathologic and Genomic Analysis of TP53 -Mutated Endometrial Carcinomas
Boroujeni, A. M., Dahoud, W., Vanderbilt, C., Chiang, S., Murali, R., Rios‐Doria, E., Alektiar, K. M., Aghajanian, C. A., Abu‐Rustum, N. R., Ladanyi, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4436 · Cited by 110 · see citing works
Self-citationERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
Kiavué, N., Cabel, L., Melaabi, S., Bataillon, G., Callens, C., Lerebours, F., Pierga, J., & Bidard, F. (2019) · Oncogene · doi:10.1038/s41388-019-1001-5 · Cited by 109 · see citing works
Collins, D. M., Conlon, N. T., Kannan, S., Verma, C. S., Eli, L. D., Lalani, A. S., & Crown, J. P. (2019) · Cancers · doi:10.3390/cancers11060737 · Cited by 108 · see citing works
Self-citationSmyth, L. M., Piha-Paul, S. A., Won, H. H., Schram, A. M., Saura, C., Loi, S., Lu, J. M., Shapiro, G. I., Juric, D., Mayer, I. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0966 · Cited by 108 · see citing works
Self-citationCroessmann, S., Formisano, L., Kinch, L. N., Ericsson, P. I. G., Sudhan, D. R., Nagy, R. J., Mathew, A., Bernicker, E., Cristofanilli, M., He, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1544 · Cited by 107 · see citing works
Self-citationLongitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials
Staffaroni, A. M., Ljubenkov, P. A., Kornak, J., Cobigo, Y., Datta, S., Marx, G., Walters, S. M., Chiang, K., Olney, N., Elahi, F. M., et al. (2019) · Brain · doi:10.1093/brain/awy319 · Cited by 105 · see citing works
Hanker, A. B., Brown, B. P., Meiler, J., Marín, A., Jayanthan, H. S., Ye, D., Lin, C.-C. A., Akamatsu, H., Lee, K., Chatterjee, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2021.06.001 · Cited by 104 · see citing works
Self-citationLobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors
Christgen, M., Cserni, G., Floris, G., Marchiò, C., Djerroudi, L., Kreipe, H. H., Derksen, P. W. B., & Vincent‐Salomon, A. (2021) · Cancers · doi:10.3390/cancers13153695 · Cited by 104 · see citing works
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
Subramanian, J., Katta, A., Masood, A., Vudem, D. R., & Kancha, R. K. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0845 · Cited by 102 · see citing works
Molecular profiling and molecular classification of endometrioid ovarian carcinomas
Cybulska, P., Paula, A. D. C., Tseng, J. H., Leitão, M. M., Bashashati, A., Huntsman, D. D., Nazeran, T. M., Aghajanian, C. A., Abu‐Rustum, N. R., DeLair, D. F., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.07.012 · Cited by 101 · see citing works
- Authors
- Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J., Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler Jr, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J., & Solit, D. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Vall d'Hebron Hospital Universitari (ES)
- Dana-Farber Cancer Institute (US)
- USC Norris Comprehensive Cancer Center (US)
- Vanderbilt University (US)
- Peter MacCallum Cancer Centre (AU)
- Washington University in St. Louis (US)
- Puma Biotechnology (United States) (US)
- Corresponding author
- Hyman, David M.
- ORCID
- Hyman, David M.
- Piha-Paul, Sarina A.
- Won, Helen
- Rodon, Jordi
- Saura, Cristina
- Shapiro, Geoffrey I.
- Juric, Dejan
- Quinn, David I.
- Mayer, Ingrid A.
- Boni, Valentina
- Calvo, Emiliano
- Loi, Sherene
- Lockhart, Albert C.
- Erinjeri, Joseph P.
- Scaltriti, Maurizio
- Ulaner, Gary A.
- Patel, Juber
- Bouvier, Nancy
- Murali, Rajmohan
- Schram, Alison M.
- Smyth, Lillian M.
- Jhaveri, Komal
- Li, Bob T.
- Drilon, Alexander
- Harding, James J.
- Iyer, Gopa
- Taylor, Barry S.
- Berger, Michael F.
- Xu, Feng
- Eli, Lisa D.
- Lalani, Alshad S.
- Bryce, Richard P.
- Arteaga, Carlos L.
- Solit, David B.
- Venue
- Nature
- Published
- 2018-01-31
- Volume
- 554
- Issue
- 7691
- Pages
- 189-194
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5808581
- OpenAlex
- W2785610956
- Cited by
- 780
- References
- 54
- Citations by year
- 2026: 40 · 2025: 64 · 2024: 89 · 2023: 99 · 2022: 113 · 2021: 103 · 2020: 113 · 2019: 86 · 2018: 69
- FWCI
- 34.53
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-02-12)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- Puma Biotechnology
- National Institutes of Health (UL1TR000371)
- National Cancer Institute (R01CA204749, U01CA180964, R01CA080195, P50CA098131, P30CA008748, P30CA016672, T32CA009207, R25CA020449, P30CA014089)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- HER2 mutation, ERBB2, HER3, neratinib, basket trials, breast cancer, biliary tract cancer, cervical cancer, targeted therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Quinolines, Cohort Studies, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Mutation, Missense, Receptor, ErbB-3, Protein Kinase Inhibitors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
